170 results on '"Melchers WJG"'
Search Results
2. Laryngeal Carcinoma in Patients With Inflammatory Bowel Disease: Clinical Outcomes and Risk Factors
- Author
-
van de Ven, Steffi, Derikx, L, Nagtegaal, ID, van Herpen, CM, Takes, RP, Melchers, WJG, Pierik, M, van den Heuvel, T, Verhoeven, RH, Hoentjen, F, Nissen, LHC, van de Ven, Steffi, Derikx, L, Nagtegaal, ID, van Herpen, CM, Takes, RP, Melchers, WJG, Pierik, M, van den Heuvel, T, Verhoeven, RH, Hoentjen, F, and Nissen, LHC
- Published
- 2020
3. Adjuvant VACcination against HPV in surgical treatment of Cervical Intra-epithelial Neoplasia (VACCIN study) a study protocol for a randomised controlled trial
- Author
-
Laar, Ralf, Hofhuis, W, Duijnhoven, RG, Polinder, Suzanne, Melchers, WJG, Kemenade, Folkert, Bekkers, RLM, Beekhuizen, Heleen, Laar, Ralf, Hofhuis, W, Duijnhoven, RG, Polinder, Suzanne, Melchers, WJG, Kemenade, Folkert, Bekkers, RLM, and Beekhuizen, Heleen
- Published
- 2020
4. Genome-wide microRNA analysis of HPV-positive self-samples yields novel triage markers for early detection of cervical cancer
- Author
-
Snoek, BC, Verlaat, W, Babion, I, Novianti, P W, van de Wiel, MA, Wilting, Saskia, van Trommel, NE, Bleeker, MCG, Massuger, L, Melchers, WJG, Sie, D, Heideman, DAM, Snijders, PJF, Meijer, C, Steenbergen, RDM, and Medical Oncology
- Subjects
SDG 3 - Good Health and Well-being - Published
- 2019
5. Introduction of primary screening using high-risk HPV DNA detection in the Dutch cervical cancer screening programme: a population-based cohort study
- Author
-
Aitken, Clare, Agt, Heleen, Siebers, AG, van Kemenade, Folkert, Niesters, HGM, Melchers, WJG, Vedder, JEM, Schuurman, R (Rob), van den Brule, AJC, van der Linden, HC, Hinrichs, JWJ, Molijn, A, Hoogduin, KJ, van Hemel, BM, Driesprong - de Kok, Inge, Aitken, Clare, Agt, Heleen, Siebers, AG, van Kemenade, Folkert, Niesters, HGM, Melchers, WJG, Vedder, JEM, Schuurman, R (Rob), van den Brule, AJC, van der Linden, HC, Hinrichs, JWJ, Molijn, A, Hoogduin, KJ, van Hemel, BM, and Driesprong - de Kok, Inge
- Published
- 2019
6. Surveillance-embedded genomic outbreak resolution of methicillin-susceptibleStaphylococcus aureusin a neonatal intensive care unit
- Author
-
Cremers, AJH, primary, Coolen, JPM, additional, Bleeker-Rovers, CP, additional, van der Geest-Blankert, ADJ, additional, Haverkate, D, additional, Hendriks, H, additional, Henriet, SSV, additional, Huynen, MA, additional, Kolwijck, E, additional, Liem, D, additional, Melchers, WJG, additional, Rossen, JW, additional, Zoll, J, additional, van Heijst, A, additional, Hopman, J, additional, and Wertheim, HFL, additional
- Published
- 2019
- Full Text
- View/download PDF
7. The clinical value of HPV genotyping in triage of women with high-risk-HPV-positive self-samples
- Author
-
Ebisch, RMF, de Kuyper-de Ridder, GM, Bosgraaf, RP, Massuger, LFAG, IntHout, J, Verhoef, VMJ, Heideman, DAM, Snijders, PJF, Meijer, CJLM, van Kemenade, Folkert, Bulten, J, Siebers, AG, Bekkers, RLM, Melchers, WJG, and Pathology
- Subjects
SDG 3 - Good Health and Well-being ,female genital diseases and pregnancy complications - Abstract
Cytology alone, or combined with HPV16/18 genotyping, might be an acceptable method for triage in hrHPV-cervical cancer screening. Previously studied HPV-genotype based triage algorithms are based on cytology performed without knowledge of hrHPV status. The aim of this study was to explore the value of hrHPV genotyping combined with cytology as triage tool for hrHPV-positive women. 520 hrHPV-positive women were included from a randomised controlled self-sampling trial on screening non-attendees (PROHTECT-3B). Eighteen baseline triage strategies were evaluated for cytology and hrHPV genotyping (Roche Cobas 4800) on physician-sampled triage material. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), referral rate, and number of referrals needed to diagnose (NRND) were calculated for CIN2+ and CIN3+. A triage strategy was considered acceptable if the NPV for CIN3+ was >98%, combined with maintenance or improvement of sensitivity and an increase in specificity in reference to the comparator, being cytology with a threshold of atypical cells of undetermined significance (ASC-US). Three triage strategies met the criteria: HPV16+ and/or >LSIL; HPV16+ and/or >HSIL; (HPV16+ and/or HPV18+) and/or >HSIL. Combining HPV16+ and/or >HSIL yielded the highest specificity (74.9%, 95% CI 70.5-78.9), with a sensitivity (94.4%, 95% CI 89.0-97.7) similar to the comparator (93.5%, 95% CI 87.7-97.1), and a decrease in referral rate from 52.2% to 39.5%. In case of prior knowledge of hrHPV presence, triage by cytology testing can be improved by adjusting its threshold, and combining it with HPV16/18 genotyping. These strategies improve the referral rate and specificity for detecting CIN3+ lesions, while maintaining adequate sensitivity.
- Published
- 2016
8. Quantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014
- Author
-
Mohammadi, F, Hashemi, S J, Zoll, J, Melchers, WJG, Rafati, Haleh, Dehghan, P, Rezaie, S, Tolooe, A, Tamadon, Y, van der Lee, H A, Verweij, PE, Seyed Mousavi Tasieh, Seyed, Biochemistry, and Medical Microbiology & Infectious Diseases
- Subjects
Antifungal Agents ,Aspergillus fumigatus ,Gene Expression ,Microbial Sensitivity Tests ,Sequence Analysis, DNA ,Iran ,Triazoles ,Polymorphism, Single Nucleotide ,Epidemiology and Surveillance ,Fungal Proteins ,Cytochrome P-450 Enzyme System ,Drug Resistance, Fungal ,Aspergillosis ,Humans ,Voriconazole ,Itraconazole ,DNA, Fungal ,Mycological Typing Techniques ,Promoter Regions, Genetic ,Microsatellite Repeats ,Retrospective Studies - Abstract
We employed an endpoint genotyping method to update the prevalence rate of positivity for the TR34/L98H mutation (a 34-bp tandem repeat mutation in the promoter region of the cyp51A gene in combination with a substitution at codon L98) and the TR46/Y121F/T289A mutation (a 46-bp tandem repeat mutation in the promoter region of the cyp51A gene in combination with substitutions at codons Y121 and T289) among clinical Aspergillus fumigatus isolates obtained from different regions of Iran over a recent 5-year period (2010 to 2014). The antifungal activities of itraconazole, voriconazole, and posaconazole against 172 clinical A. fumigatus isolates were investigated using the European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution method. For the isolates with an azole resistance phenotype, the cyp51A gene and its promoter were amplified and sequenced. In addition, using a LightCycler 480 real-time PCR system, a novel endpoint genotyping analysis method targeting single-nucleotide polymorphisms was evaluated to detect the L98H and Y121F mutations in the cyp51A gene of all isolates. Of the 172 A. fumigatus isolates tested, the MIC values of itraconazole (≥16 mg/liter) and voriconazole (>4 mg/liter) were high for 6 (3.5%). Quantitative analysis of single-nucleotide polymorphisms showed the TR34/L98H mutation in the cyp51A genes of six isolates. No isolates harboring the TR46/Y121F/T289A mutation were detected. DNA sequencing of the cyp51A gene confirmed the results of the novel endpoint genotyping method. By microsatellite typing, all of the azole-resistant isolates had genotypes different from those previously recovered from Iran and from the Dutch TR34/L98H controls. In conclusion, there was not a significant increase in the prevalence of azole-resistant A. fumigatus isolates harboring the TR34/L98H resistance mechanism among isolates recovered over a recent 5-year period (2010 to 2014) in Iran. A quantitative assay detecting a single-nucleotide polymorphism in the cyp51A gene of A. fumigatus is a reliable tool for the rapid screening and monitoring of TR34/L98H- and TR46/Y121F/T289A-positive isolates and can easily be incorporated into clinical mycology algorithms.
- Published
- 2015
9. Successful treatment of azole-resistant invasive aspergillosis in a bottlenose dolphin with high-dose posaconazole
- Author
-
Bunskoek, PE, Seyedmousavi, S, Gans, SJM, van Vierzen, PBJ, Melchers, WJG, van Elk, CE, Mouton, Johan, Verweij, PE, Bunskoek, PE, Seyedmousavi, S, Gans, SJM, van Vierzen, PBJ, Melchers, WJG, van Elk, CE, Mouton, Johan, and Verweij, PE
- Published
- 2017
10. Comparative performance of novel self-sampling methods in detecting high-risk human papillomavirus in 30,130 women not attending cervical screening
- Author
-
Bosgraaf, RP, Verhoef, VMJ, Massuger, LFAG, Siebers, AG, Bulten, J, de Kuyper-de Ridder, GM, Meijer, CJM, Snijders, PJF, Heideman, DAM, IntHout, J, van Kemenade, Folkert, Melchers, WJG, Bekkers, RLM, and Pathology
- Subjects
SDG 3 - Good Health and Well-being ,female genital diseases and pregnancy complications - Abstract
We determined whether the participation rate for a brush-based cervicovaginal self-sampling device is noninferior to the participation rate for a lavage-based one for testing for hrHPV (high-risk human papillomavirus). Additionally, positivity rates for hrHPV, the detection rates for cervical intraepithelial neoplasia grades 2 and 3 or worse (CIN2+/3+), and user comfort were compared. A total of 35,477 non-responders of the regular cervical screening program aged 33-63 years were invited to participate. Eligible women (n=30,130) were randomly assigned to receive either a brush-based or a lavage-based device, and a questionnaire for reporting user convenience. Self-sampling responders testing hrHPV-positive were invited for a physician-taken sample for cytology; triage-positive women were referred for colposcopy. A total of 5,218 women participated in the brush-based sampling group (34.6%) and 4809 women in the lavage-based group (31.9%), i.e. an absolute difference of 2.7% (95%CI 1.8-4.2). The hrHPV-positivity rates in the two groups were identical (8.3%, relative risk (RR) 0.99, 95%CI 0.87-1.13). The detection of CIN2+ and CIN3+ in the brush group (2.0% for CIN2+; 1.3% for CIN3+) was similar to that in the lavage group (1.9% for CIN2+; 1.0% for CIN3+) with a cumulative RR of 1.01, 95%CI 0.83-1.24 for CIN2+ and 1.25, 95%CI 0.92-1.70 for CIN3+. The two self-sampling devices performed similarly in user comfort. In conclusion, offering a brush-based device to non-responders is noninferior to offering a lavage-based device in terms of participation. The two self-sampling methods are equally effective in detecting hrHPV, CIN2+/CIN3+ and are both well accepted. What's new? If people won't come into the clinic to get tested for HPV, send the test to them: that's the public health strategy the Netherlands will employ beginning in 2016. This study compared two methods of self-sampling for HPV, one brush based and one lavage based. The authors measured participation rates, user comfort, how often each method detected the virus, and how often neoplasias were detected. They found non-inferiority in the participation rates, and in all other measures the two methods performed equally well.
- Published
- 2015
11. Validation of the FAM19A4/mir124-2 DNA methylation test for both lavage- and brush-based self-samples to detect cervical (pre)cancer in HPV-positive women
- Author
-
De Strooper, LMA, Verhoef, VMJ, Berkhof, J, Hesselink, AT, de Bruin, HME, van Kemenade, Folkert, Bosgraaf, RP, Bekkers, RLM, Massuger, LFAG, Melchers, WJG, Steenbergen, RDM, Snijders, PJF, Meijer, CJLM, Heideman, DAM, De Strooper, LMA, Verhoef, VMJ, Berkhof, J, Hesselink, AT, de Bruin, HME, van Kemenade, Folkert, Bosgraaf, RP, Bekkers, RLM, Massuger, LFAG, Melchers, WJG, Steenbergen, RDM, Snijders, PJF, Meijer, CJLM, and Heideman, DAM
- Abstract
Objectives. DNA methylation analysis of cancer-related genes is a promising tool for HPV-positive women to identify those with cervical (pre)cancer (CIN3+) in need of treatment. However, clinical performance of methylation markers can be influenced by the sample type utilized. We describe a multiplex quantitative methylation-specific PCR that targets FAM19A4 and mir124-2 loci, to detect CIN3+ using both HPV-positive lavage- and brush self-samples. Methods. We determined methylation thresholds for clinical classification using HPV-positive training sets comprising lavage self-samples of 182 women (including 40 with CIN3+) and brush self-samples of 224 women (including 61 with CIN3+). Subsequently, independent HPV-positive validation sets of 389 lavage self-samples (including 78 with CIN3+), and 254 brush self-samples (including 72 with CIN3+) were tested using the preset thresholds. Furthermore, the clinical performance of combined methylation analysis and HPV16/18 genotyping was determined. Results. Training set analysis revealed similar FAM19A4 and mir124-2 thresholds for both self-sample types to yield highest CIN3+ sensitivity at 70% specificity. Validation set analysis resulted in a CIN3+ sensitivity of 70.5% (95%CI: 60.4-80.6) at a specificity of 67.8% (95%CI: 62.7-73.0) for lavage self-samples, and a CIN3+ sensitivity of 69.4% (95%CI: 58.8-80.1) at a 76.4% (95%CI: 70.2-82.6) specificity for brush self-samples. In combination with HPV16/18 genotyping, CIN3+ sensitivity and specificity were 88.5% (95%CI: 81.4-95.6) and 46.0% (95%CI: 40.4-51.5) for lavage self-samples, and 84.7% (95%CI: 76.4-93.0) and 54.9% (95%CI: 47.7-62.2) for brush self-samples. Conclusions. FAM19A4/mir124-2 methylation analysis performs equally well in HPV-positive lavage- and brush self-samples to identify women with CIN3+. In combination with HPV16/18 genotyping, significantly higher CIN3+ sensitivities are obtained, at decreased specificity. (C) 2016 The Authors. Published by Elsevier Inc
- Published
- 2016
12. Large two-centre study into the prevalence of Mycoplasma genitalium and Trichomonas vaginalis in the Netherlands
- Author
-
de Jong, AS, primary, Rahamat-Langendoen, JC, additional, van Alphen, PTW, additional, Hilt, N, additional, van Herk, CMC, additional, Pont, SBEH, additional, Melchers, WJG, additional, and van de Bovenkamp, JHB, additional
- Published
- 2016
- Full Text
- View/download PDF
13. Evidence supporting see-and-treat management of cervical intraepithelial neoplasia: a systematic review and meta-analysis
- Author
-
Ebisch, RMF, primary, Rovers, MM, additional, Bosgraaf, RP, additional, van der Pluijm-Schouten, HW, additional, Melchers, WJG, additional, van den Akker, PAJ, additional, Massuger, LFAG, additional, and Bekkers, RLM, additional
- Published
- 2015
- Full Text
- View/download PDF
14. Wat zijn de huidige mogelijkheden voor de polymerase-kettingreactie in de klinisch-microbiologische praktijk?
- Author
-
Belkum, Alex, Melchers, WJG, and Medical Microbiology & Infectious Diseases
- Published
- 2002
15. Moleculaire diagnostiek van infectieziekten
- Author
-
Belkum, Alex, Melchers, WJG, Schellekens, H., van Bragt, P.H., Olijve, W., van der Weele, C.N., and Medical Microbiology & Infectious Diseases
- Published
- 2001
16. Study on microbial persistence in end stage idiopathic dilated cardiomyopathy
- Author
-
de Leeuw, N, Melchers, WJG, Balk, Aggie, Jonge, N, Galama, JMD, and Cardiology
- Published
- 1999
17. A generalized skin eruption in a human immunodeficiency virus–infected boy
- Author
-
Kroft, EBM, primary, Melchers, WJG, additional, Blokx, WAM, additional, de Hoop, D, additional, and Warris, A, additional
- Published
- 2008
- Full Text
- View/download PDF
18. Evidence supporting see-and-treat management of cervical intraepithelial neoplasia: a systematic review and meta-analysis.
- Author
-
Ebisch, RMF, Rovers, MM, Bosgraaf, RP, Pluijm‐Schouten, HW, Melchers, WJG, Akker, PAJ, Massuger, LFAG, and Bekkers, RLM
- Subjects
TREATMENT of cervical intraepithelial neoplasia ,DISEASE management ,META-analysis ,SYSTEMATIC reviews ,OVERTREATMENT of cancer ,HISTOLOGY ,COLPOSCOPY ,SUBGROUP analysis (Experimental design) ,CERVIX uteri ,ELECTROSURGERY ,MEDICAL referrals ,PAP test ,CERVIX uteri tumors ,DISEASE incidence ,CERVICAL intraepithelial neoplasia - Abstract
Background: Studies of see-and-treat management of cervical intraepithelial neoplasia (CIN) vary in their inclusion criteria, resulting in a broad range of overtreatment rates.Objectives: To determine overtreatment rates in see-and-treat management of women referred for colposcopy because of suspected CIN, in order to define circumstances supporting see-and-treat management.Search Strategy: MEDLINE, EMBASE, and the Cochrane Library were searched from inception up to 12 May 2014.Selection Criteria: Studies of see-and-treat management in women with a reported cervical smear result, colposcopic impression, and histology result were included.Data Collection and Analysis: Methodological quality was assessed with the Newcastle-Ottawa scale. We used the inverse variance method for pooling incidences, and a random-effects model was used to account for heterogeneity between studies. Overtreatment was defined as treatment in patients with no CIN or CIN1.Main Results: Thirteen studies (n = 4611) were included. The overall overtreatment rate in women with a high-grade cervical smear and a high-grade colposcopic impression was 11.6% (95% CI 7.8-15.3%). The overtreatment rate in women with a high-grade cervical smear and low-grade colposcopic impression was 29.3% (95% CI 16.7-41.9%), and in the case of a low-grade smear and high-grade colposcopic impression it was 46.4% (95% CI 15.7-77.1%). In women with a low-grade smear and low-grade colposcopic impression, the overtreatment rate was 72.9% (95% CI 68.1-77.7%).Author's Conclusions: The pooled overtreatment rate in women with a high-grade smear and high-grade colposcopic impression is at least comparable with the two-step procedure, which supports the use of see-and-treat management in this subgroup of women.Tweetable Abstract: See-and-treat management is justified in the case of a high-grade smear and a high-grade colposcopic impression. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
19. Outbreak of Amoxicillin-Resistant Haemophilus influenzae Type b: Variable Number of Tandem Repeats as Novel Molecular Markers
- Author
-
Belkum, Alex, Melchers, WJG, IJsseldijk, C, Nohlmans, L, Verbrugh, Henri, Meis, JFGM, Belkum, Alex, Melchers, WJG, IJsseldijk, C, Nohlmans, L, Verbrugh, Henri, and Meis, JFGM
- Published
- 1997
20. The diagnostic value of PCR for the detection of enteroviral infections
- Author
-
de Leeuw, N, primary, Melchers, WJG, additional, Willemse, DFM, additional, Balk, AHMM, additional, de Jonge, N, additional, and Galama, JMD, additional
- Published
- 1994
- Full Text
- View/download PDF
21. Polymerase chain reaction as a diagnostic tool for invasive aspergillosis: evaluation in bronchoalveolar lavage fluid from low risk patients
- Author
-
Verweij, PE, primary, Meis, JFGM, additional, van den Hurk, P, additional, De Pauw, BE, additional, Hoogkamp-Korstanje, JAA, additional, and Melchers, WJG, additional
- Published
- 1994
- Full Text
- View/download PDF
22. Neuroinvasion by human herpesvirus type 7 in a case of exanthem subitum with severe neurologic manifestations.
- Author
-
van den Berg JSP, van Zeijl JH, Rotteveel JJ, Melchers WJG, Gabreëls FJM, Galama JMD, van den Berg, J S, van Zeijl, J H, Rotteveel, J J, Melchers, W J, Gabreëls, F J, and Galama, J M
- Published
- 1999
- Full Text
- View/download PDF
23. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America
- Author
-
Costagliola, D., Dabis, F., Monforte, Ad, Wolf, F., Egger, M., Fatkenheuer, G., Gill, J., Hogg, R., Justice, A., Ledergerber, B., Lundgren, J., May, M., Phillips, A., Reiss, P., Sabin, C., Staszewski, S., Sterne, J., Weller, I., Beckthold, B., Yip, B., Dauer, B., Fusco, J., Grabar, S., Lanoy, E., Junghans, C., Lavignolle, V., Leth, F., Pereira, E., Pezzotti, P., Schmeisser, N., Billaud, E., Boue, F., Duval, X., Duvivier, C., Enel, P., Fournier, S., Gasnault, J., Gaud, C., Gilquin, J., Khuong, Ma, Lang, Jm, Mary-Krause, M., Matheron, S., Meyohas, Mc, Pialoux, G., Poizot-Martin, I., Pradier, C., Rouveix, E., Salmon-Ceron, D., Sobel, A., Tattevin, P., Tissot-Dupont, H., Yasdanpanah, Y., Aronica, E., Tirard-Fleury, V., Tortay, I., Abgrall, S., Guiguet, M., Leneman, H., Lievre, L., Potard, V., Saidi, S., Vilde, Jl, Leport, C., Yeni, P., Bouvet, E., Gaudebout, C., Crickx, B., Picard-Dahan, C., Weiss, L., Tisne-Dessus, D., Sicard, D., Salmon, D., Auperin, I., Viard, Jp, Roudiere, L., Delfraissy, Jf, Goujard, C., Lesprit, P., Jung, C., Meynard, Jl, Picard, O., Desplanque, N., Cadranel, J., Mayaud, C., Rozenbaum, W., Bricaire, F., Katlama, C., Herson, S., Simon, A., Decazes, Jm, Molina, Jm, Clauvel, Jp, Gerard, L., Widal, Ghlf, Sellier, P., Diemer, M., Dupont, C., Berthe, H., Saiag, P., Mortier, L., Mortier, E., Chandemerle, C., Truchis, P., Bentata, M., Honore, P., Tassi, S., Jeantils, V., Mechali, D., Taverne, B., Laurichesse, H., Gourdon, F., Lucht, F., Fresard, A., Faller, Jp, Eglinger, P., Bazin, C., Verdon, R., Peyramond, D., Boibieux, A., Touraine, Jl, Livrozet, Jm, Trepo, C., Cotte, L., Ravaux, I., Delmont, Jp, Moreau, J., Gastaut, Ja, Soubeyrand, J., Retornaz, F., Blanc, Pa, Allegre, T., Galinier, A., Ruiz, Jm, Lepeu, G., Granet-Brunello, P., Pelissier, L., Esterni, Jp, Nezri, M., Cohen-Valensi, R., Laffeuillade, A., Chadapaud, S., Reynes, J., May, T., Rabaud, C., Raffi, F., Pugliese, P., Michelet, C., Arvieux, C., Caron, F., Borsa-Lebas, F., Fraisse, P., Massip, P., Cuzin, L., Arlet-Suau, E., Legrand, Mft, Sobesky, M., Pradinaud, R., Guyon, F., Contant, M., Montroni, M., Scalise, G., Braschi, Mc, Aviano, Ar, Tirelli, U., Cinelli, R., Pastore, G., Ladisa, N., Minafra, G., Suter, F., Arici, C., Chiodo, F., Colangeli, V., Fiorini, C., Coronado, O., Carosi, G., Cadeo, Gp, Torti, C., Minardi, C., Bertelli, D., Rizzardini, G., Melzi, S., Manconi, Pe, Catanzaro, Pp, Cosco, L., Scerbo, A., Vecchiet, J., D Alessandro, M., Santoro, D., Pusterla, L., Carnevale, G., Citterio, P., Vigano, P., Mena, M., Ghinelli, F., Sighinolfi, L., Leoncini, F., Mazzotta, F., Pozzi, M., Lo Caputo, S., Angarano, G., Grisorio, B., Saracino, A., Ferrara, S., Grima, P., Tundo, P., Pagano, G., Cassola, G., Alessandrini, A., Piscopo, R., Toti, M., Chigiotti, S., Soscia, F., Tacconi, L., Orani, A., Perini, P., Scasso, A., Vincenti, A., Chiodera, F., Castelli, P., Scalzini, A., Palvarini, L., Moroni, M., Lazzarin, A., Cargnel, A., Vigevani, Gm, Caggese, L., Repetto, D., Galli, A., Merli, S., Pastecchia, C., Moioli, Mc, Esposito, R., Mussini, C., Abrescia, N., Chirianni, A., Izzo, Cm, Piazza, M., Marco, M., Viglietti, R., Manzillo, E., Nappa, S., Colomba, A., Abbadessa, V., Prestileo, T., Mancuso, S., Ferrari, C., Pizzaferri, P., Filice, G., Minoli, L., Bruno, R., Novati, S., Baldelli, F., Tinca, M., Petrelli, E., Cioppi, A., Alberici, F., Ruggieri, A., Menichetti, F., Martinelli, C., Stefano, C., La Gala, A., Ballardini, G., Rizzo, E., Magnani, G., Ursitti, Ma, Arlotti, M., Ortolani, P., Cauda, R., Dianzani, F., Ippolito, G., Antinori, A., Antonucci, G., D Elia, S., Narciso, P., Petrosillo, N., Vullo, V., Luca, A., Bacarelli, A., Zaccarelli, M., Acinapura, R., Longis, P., Brandi, A., Trotta, Mp, Noto, P., Lichtner, M., Capobianchi, MR, Carletti, F., Girardi, E., Rezza, G., Mura, Ms, Mannazzu, M., Caramello, P., Di Perri, G., Soranzo, Ml, Orofino, Gc, Arnaudo, I., Bonasso, M., Grossi, Pa, Basilico, C., Poggio, A., Bottari, G., Raise, E., Ebo, F., Lalla, F., Tositti, G., Resta, F., Loso, K., Lepri, Ac, Battegay, M., Bernasconi, E., Boni, J., Bucher, H., Burgisser, P., Cattacin, S., Cavassini, M., Dubs, R., Elzi, L., Erb, P., Fantelli, K., Fischer, M., Flepp, M., Fontana, A., Francioli, P., Furrer, H., Gorgievski, M., Hirschel, B., Kaiser, L., Kind, C., Klimkait, T., Lauper, U., Opravil, M., Paccaud, F., Pantaleo, G., Perrin, L., Piffaretti, Jc, Rickenbach, M., Rudin, C., Schmid, P., Schupbach, J., Speck, R., Telenti, A., Trkola, A., Vernazza, P., Weber, R., Yerly, S., Bronsveld, W., Hillebrand-Haverkort, Me, Prins, Jm, Bos, Jc, Schattenkerk, Jkme, Geerlings, Se, Godfried, Mh, Lange, Jma, Leth, Fc, Lowe, Sh, Meer, Jtm, Nellen, Fjb, Pogany, K., Poll, T., Ruys, Ta, Sankatsing, S., Steingrover, R., Twillert, G., Valk, M., Vonderen, Mga, Vrouenraets, Sme, Vugt, M., Wit, Fwmn, Kuijpers, Tw, Pajkrt, D., Scherpbier, Hj, Eeden, A., Ten Veen, Jh, Dam, Ps, Roos, Jc, Brinkman, K., Frissen, Phj, Weigel, Hm, Mulder, Jw, Gorp, Ecm, Meenhorst, Pl, Mairuhu, Ata, Ziekenhuis, S., Veenstra, J., Danner, Sa, Agtmael, Ma, Claessen, Fap, Perenboom, Rm, Rijkeboer, A., Vonderen, M., Richter, C., Berg, J., Leusen, R., Vriesendorp, R., Jeurissen, Fjf, Kauffmann, Rh, Koger, Elw, Bravenboer, B., Ten Napel, Chh, Kootstra, Gj, Sprenger, Hg, Miesen, Wmaj, Doedens, R., Scholvinck, Eh, Ten Kate, Rw, Houte, Dpf, Polee, M., Kroon, Fp, van den Broek, Dissel, Jt, Schippers, Ef, Schreij, G., Geest, Sv, Verbon, A., Koopmans, Pp, Keuter, M., Post, F., Ven, Ajam, Ende, Me, Gyssens, Ic, Feltz, M., Den Hollander, Jg, Marie, S., Nouwen, Jl, Rijnders, Bja, Vries, Tems, Driessen, G., Groot, R., Hartwig, N., Juttmann, Jr, Heul, C., Kasteren, Mee, Schneider, Mme, Bonten, Mjm, Borleffs, Jcc, Ellerbroek, Pm, Hoepelman, Im, Jaspers, Cajj, Schouten, I., Schurink, Cam, Geelen, Spm, Wolfs, Tfw, Blok, Wl, Tanis, Aa, Groeneveld, Php, Klinieken-Zwolle, I., Back, Nkt, Bakker, Meg, Berkhout, B., Jurriaans, S., Cuijpers, T., Rietra, Pjgm, Roozendaal, Kj, Pauw, W., Zanten, Ap, Blomberg, Bme, Savelkoul, P., Swanink, Cma, Franck, Pfh, Lampe, As, Hendriks, R., Schirm, J., Veenendaal, D., Storm, H., Weel, J., Zeijl, H., Kroes, Acm, Claas, Hcj, Bruggeman, Camva, Goossens, Vj, Galama, Jmd, Melchers, Wjg, Poort, Yag, Doornum, Gjj, Niesters, Mg, Osterhaus, Adme, Schutten, M., Buiting, Agm, Swaans, Cam, Boucher, Cab, Boel, E., Jansz, Af, Losso, M., Duran, A., Vetter, N., Karpov, I., Vassilenko, A., Clumeck, N., Wit, S., Poll, B., Colebunders, R., Machala, L., Rozsypal, H., Dalibor Sedlacek, Nielsen, J., Benfield, T., Kirk, O., Gerstoft, J., Katzenstein, T., Hansen, Abe, Skinhoj, P., Pedersen, C., Zilmer, K., Girard, Pm, Saint-Marc, T., Vanhems, P., Dietrich, M., Manegold, C., Lunzen, J., Stellbrink, Hj, Bickel, M., Goebel, Fd, Rockstroh, J., Schmidt, R., Kosmidis, J., Gargalianos, P., Sambatakou, H., Perdios, J., Panos, G., Filandras, A., Karabatsaki, E., Banhegyi, D., Mulcahy, F., Yust, I., Turner, D., Burke, M., Pollack, S., Hassoun, G., Sthoeger, Z., Maayan, S., Chiesi, A., Borghi, R., Pristera, R., Gabbuti, A., Montesarchio, E., Iacomi, F., Finazzi, R., Viksna, L., Chaplinskas, S., Hemmer, R., Staub, T., Bruun, J., Maeland, A., Ormaasen, V., Knysz, B., Gasiorowski, J., Horban, A., Prokopowicz, D., Wiercinska-Drapalo, A., Boron-Kaczmarska, A., Pynka, M., Beniowski, M., Mularska, E., Trocha, H., Antunes, F., Valadas, E., Mansinho, K., Matez, F., Duiculescu, D., Babes, V., Streinu-Cercel, A., Vinogradova, E., Rakhmanova, A., Jevtovic, D., Mokras, M., Stanekova, D., Gonzalez-Lahoz, J., Sanchez-Conde, M., Garcia-Benayas, T., Martin-Carbonero, L., Soriano, V., Clotet, B., Jou, A., Conejero, J., Tural, C., Gatell, Jm, Miro, Jm, Blaxhult, A., Karlsson, A., Pehrson, P., Soravia-Dunand, V., Kravchenko, E., Chentsova, N., Barton, S., Johnson, Am, Mercey, D., Johnson, Ma, Mocroft, A., Murphy, M., Weber, J., Scullard, G., Fisher, M., Brettle, R., Loveday, C., Gatell, J., Johnson, A., Vella, S., Gjorup, I., Friis-Moeller, N., Cozzi-Lepri, A., Bannister, W., Mollerup, D., Podlevkareva, D., Olsen, Ch, Kjaer, J., Raffanti, S., Dieterch, D., Becker, S., Scarsella, A., Fusco, G., Most, B., Balu, R., Rana, R., Beckerman, R., Ising, T., Irek, R., Johnson, B., Hirani, A., Dejesus, E., Pierone, G., Lackey, P., Irek, C., Burdick, J., Leon, S., Arch, J., Helm, Eb, Carlebach, A., Muller, A., Haberl, A., Nisius, G., Lennemann, T., Rottmann, C., Wolf, T., Stephan, C., Mosch, M., Gute, P., Locher, L., Lutz, T., Klauke, S., Knecht, G., Doerr, Hw, Sturmer, M., Hentig, N., Jennings, B., Beylot, J., Chene, G., Dupon, M., Longy-Boursier, M., Pellegrin, Jl, Ragnaud, Jm, Salamon, R., Thiebaut, R., Lewden, C., Lawson-Ayayi, S., Mercie, P., Moreau, Jf, Moriat, P., Bernard, N., Lacoste, D., Malvy, D., Neau, D., Blaizeau, Mj, Decoin, M., Delveaux, S., Hannapier, C., Labarrere, S., Lavignolle-Aurillac, V., Uwamaliya-Nziyumvira, B., Palmer, G., Touchard, D., Balestre, E., Alioum, A., Jacqmin-Gadda, H., Morlat, P., Bonarek, M., Bonnet, F., Coadou, B., Gellie, P., Nouts, C., Bocquentin, F., Dutronc, H., Lafarie, S., Aslan, A., Pistonne, T., Thibaut, P., Vatan, R., Chambon, D., La Taille, C., Cazorla, C., Ocho, A., Castera, L., Fleury, H., Lafon, Me, Masquelier, B., Pellegrin, I., Breilh, D., Blanco, P., Loste, P., Caunegre, L., Bonnal, F., Farbos, S., Ferrand, M., Ceccaldi, J., Tchamgoue, S., Witte, S., Buy, E., Alexander, C., Barrios, R., Braitstein, P., Brumme, Z., Chan, K., Cote, H., Gataric, N., Geller, J., Guillemi, S., Harrigan, Harris, M., Joy, R., Levy, A., Montaner, J., Montessori, V., Palepu, A., Phillips, E., Phillips, P., Press, N., Tyndall, M., Wood, E., Ballinger, J., Bhagani, S., Breen, R., Byrne, P., Carroll, A., Cropley, I., Cuthbertson, Z., Drinkwater, T., Fernandez, T., Geretti, Am, Murphy, G., Ivens, D., Johnson, M., Kinloch-De Loes, S., Lipman, M., Madge, S., Prinz, B., Bell, Dr, Shah, S., Swaden, L., Tyrer, M., Youle, M., Chaloner, C., Gumley, H., Holloway, J., Puradiredja, D., Sweeney, J., Tsintas, R., Bansi, L., Fox, Z., Lampe, F., Smith, C., Amoah, E., Clewley, G., Dann, L., Gregory, B., Jani, I., Janossy, G., Kahan, M., Thomas, M., Gill, Mj, Read, R., Schmeisser, V., Voigt, K., Wasmuth, Jc, Wohrmann, A., and Antiretroviral Therapy Cohort Coll
24. Multiple-triazole-resistant aspergillosis.
- Author
-
Verweij PE, Mellado E, and Melchers WJG
- Published
- 2007
25. Colposcopy referrals and CIN3 detection after triage by host cell DNA methylation and/or HPV genotyping in HPV positive women with low-grade cytology from a population-based Dutch primary HPV screening trial.
- Author
-
Verhoef L, Bleeker MCG, Polman N, Kroon KR, Steenbergen RDM, Ebisch RMF, Melchers WJG, Bekkers RLM, Molijn AC, van Kemenade F, Meijer CJLM, Heideman DAM, and Berkhof J
- Subjects
- Humans, Female, Adult, Middle Aged, Netherlands, Genotype, Papillomaviridae genetics, Papillomaviridae isolation & purification, MicroRNAs genetics, Cytokines, DNA Methylation, Colposcopy, Uterine Cervical Dysplasia virology, Uterine Cervical Dysplasia diagnosis, Uterine Cervical Dysplasia genetics, Papillomavirus Infections virology, Papillomavirus Infections diagnosis, Referral and Consultation, Triage methods, Uterine Cervical Neoplasms virology, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms pathology, Early Detection of Cancer methods
- Abstract
High-risk HPV (hrHPV)-based screening has led to many unnecessary colposcopy referrals, mainly because of direct referral after low-grade cytology (ASC-US/LSIL). DNA methylation and genotyping tests on ASC-US/LSIL samples have the potential to significantly improve the efficiency of screening. In this study, 12 triage strategies were constructed from FAM19A4/miR124-2 or ASCL1/LHX8 methylation, HPV16/18 or HPV16/18/31/33/45 genotyping and 1-year repeat cytology. The performance was evaluated on 215 hrHPV-positive ASC-US/LSIL samples from the IMPROVE trial (NTR5078). Performance was measured by colposcopy referral rate, positive predictive value (PPV) for detecting precancer (CIN3), and negative predictive value (NPV). To evaluate efficiency, strategies were ordered by the cumulative colposcopy referral rate after 1-year cytology and compared by the marginal PPV to detect one additional CIN3 (mPPV). The most conservative strategy (referral when HPV16/18 and FAM19A4/miR124 methylation results are positive) had a direct referral rate of 5.2%, a cumulative referral rate after 1-year cytology of 54.1%, and mPPV of 19.3%. Replacing HPV16/18 by HPV16/18/31/33/45 increased the cumulative 1-year referral rate to 54.6%, and yielded an mPPV of 10.0%. Similar results were obtained for strategies with ASCL1/LHX8 methylation. Of all strategies, referral after an HPV16/18/31/33/45 positive, ASCL1/LHX8 methylation-positive, and/or 1-year cytology-positive result yielded the highest direct and cumulative 1-year colposcopy referral rates of 64.4% and 79.1%, respectively. The NPVs after 1-year cytology varied between 98.1% and 99.4%, warranting a return to routine screening. Altogether, DNA methylation-based triage strategies are recommended as they are discriminative for CIN3 and control the number of immediate colposcopy referrals., (© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
- Published
- 2025
- Full Text
- View/download PDF
26. Interlaboratory assays from the fungal PCR Initiative and the Modimucor Study Group to improve qPCR detection of Mucorales DNA in serum: one more step toward standardization.
- Author
-
Rocchi S, Scherer E, White PL, Guitton A, Alanio A, Botterel F, Bougnoux ME, Buitrago MJ, Cogliati M, Cornu M, Damiani C, Denis J, Dupont D, Fuchs S, Gorton R, Haas P-J, Hagen F, Hare R, Iriart X, Klaassen CHW, Lackner M, Lengerova M, Melchers WJG, Morio F, Poirier P, Springer J, Valot S, Willinger B, Mazzi C, Cruciani M, Barnes R, Donnelly JP, Loeffler J, and Millon L
- Subjects
- Humans, Molecular Diagnostic Techniques standards, Molecular Diagnostic Techniques methods, Mucorales genetics, Mucorales isolation & purification, DNA, Fungal blood, DNA, Fungal genetics, Real-Time Polymerase Chain Reaction standards, Real-Time Polymerase Chain Reaction methods, Mucormycosis diagnosis, Mucormycosis microbiology, Mucormycosis blood, Sensitivity and Specificity
- Abstract
The aim of this study was to identify parameters influencing DNA extraction and PCR amplification efficiencies in an attempt to standardize Mucorales qPCR. The Fungal PCR Initiative Mucorales Laboratory Working Group distributed two panels of simulated samples to 26 laboratories: Panel A (six sera spiked with Mucorales DNA and one negative control serum) and Panel B (six Mucorales DNA extracts). Panel A underwent DNA extraction in each laboratory according to the local procedure and were sent to a central laboratory for testing using three different qPCR techniques: one in-house qPCR assay and two commercial assays (MucorGenius and Fungiplex). Panel B DNA extracts were PCR amplified in each laboratory using local procedures: nine in-house qPCR assays and two commercial kits (MucorGenius and MycoGENIE). All data were compiled and anonymously analyzed at the central laboratory. For Panel A, a total of six different automated platforms and five manual extraction methods were used. Positive rates were 64%, 70%, and 89%, for the MucorGenius, Fungiplex, and the in-house qPCR assay, respectively. Using a large volume of serum for DNA extraction provided the highest analytical sensitivity (82.5% for 1 mL compared with 62.7% for smaller volumes, P < 0.01). For Panel B, five in-house qPCR assays and two commercial kits had >78% positivity. Using larger PCR input volumes (≥7 µL) was associated with the highest sensitivity at 95.5% compared to 58.3% when lower input volumes were used ( P < 0.01). Using larger sample volumes for nucleic acid extraction and DNA template volumes for PCR amplification significantly improves the performance of Mucorales qPCR when testing serum., Importance: Mucormycosis is a life-threatening mold infection affecting immunosuppressed patients but also other patients with diabetes or trauma. Better survival is linked to shorter delays in diagnosis and treatment initiation. Detection of Mucorales-free DNA in serum or plasma using quantitative PCR allows a prompt diagnosis and earlier treatment. Several techniques and protocols of quantitative Mucorales PCR are used in Europe, and improving performance remains a common objective of laboratories participating in the fungal PCR Initiative Working Group. This study, which combined results from 26 laboratories in Europe, showed that the main parameters underpinning sensitivity are the preanalytical variables (volume of serum used for DNA extraction and DNA template volume), irrespective of the extraction platforms and qPCR assay/platform., Competing Interests: The authors declare no conflict of interest.
- Published
- 2025
- Full Text
- View/download PDF
27. Evaluation of environmental factors related to Aspergillus fumigatus azole resistance in the Netherlands.
- Author
-
Cogliati M, Buil JB, Esposto MC, Prigitano A, Romanò L, and Melchers WJG
- Subjects
- Netherlands, Antifungal Agents pharmacology, Aspergillosis microbiology, Aspergillosis drug therapy, Humans, Aspergillus fumigatus drug effects, Drug Resistance, Fungal, Azoles pharmacology
- Abstract
Emergence of azole-resistant Aspergillus fumigatus represents a concern for public health worldwide. Here we applied a spatial analysis to a large number of records on A. fumigatus azole resistance in the Netherlands to evaluate the relationship of a set of environmental factors with the emergence of resistant isolates and to identify the potential risk areas. A total of 1850 aspergillosis cases were included in the analysis: 1559 caused by wild-type (WT) and 291 by azole-resistant (RES) strains. High-resolution maps containing environmental variables (climate, crop cultivations) were used as layers for spatial analysis. QGIS software was used for transformation and calculation of layers, and visualizing maps, whereas MaxEnt software was used to perform spatial analysis. A separate distribution map for WT and RES was generated using each layer, then the ratio between RES and WT suitability was calculated, and a new map was generated showing the areas where suitability of RES was higher than WT (ratio > 1). Layers presenting areas with a ratio > 1 were then used for a further analysis including all these layers together to generate a final risk map, to identify the most contributing environmental variables, and to estimate the number of people potentially exposed to the risk. Results showed that the areas with the highest RES/WT ratio were associated with the following variables: legume cultivations ratio 1.5-2.7; fruit tree plantations, ratio 2.1; dump sites and artificial sites, ratio 2.3-2.7; spring minimum and mean temperatures, ratio 1.6-1.8. Areas with medium, high, and very high risk covered a surface of about 2330 km
2 and people exposed were >319,000, with Zeeland and Noord-Holland being the provinces with the highest risk. All together these results suggest that azole-resistance emergence is a complex phenomenon depending on a multitude of environmental variables that are not yet been fully explored., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)- Published
- 2025
- Full Text
- View/download PDF
28. Development of a large-scale rapid LAMP diagnostic testing platform for pandemic preparedness and outbreak response.
- Author
-
van Beuningen R, Jim KK, Boot M, Ossendrijver M, Keijser BJF, van de Bovenkamp JHB, Melchers WJG, and Kievits T
- Abstract
The coronavirus disease 2019 (COVID-19) pandemic underscored the necessity for rapid and efficient diagnostic testing to mitigate outbreaks and control disease transmission. While real-time reverse transcriptase quantitative PCR (RT-qPCR) has been the gold standard due to its high sensitivity and specificity, its logistical complexities and extended turnaround times highlighted the need for alternative molecular methods and non-standard equipment and consumables not subject to supply chain pressure. Loop-mediated isothermal amplification (LAMP) offers several advantages over RT-qPCR, including faster processing time, assay flexibility and cost-effectiveness. During the pandemic, LAMP was successfully demonstrated as a viable alternative to RT-qPCR for SARS-Related Coronavirus 2 detection. However, due to a 100 to 1,000-fold increase in testing volumes, there was an imminent need for automating and scaling up existing LAMP testing workflows leveraging a robotic infrastructure, while retaining analytical performance and cost-effectiveness. In 2020, the Foundation TOMi started the "TOMi corona initiative" to develop and validate a high-throughput, end-to-end, automated, scalable single-step RNA purification, and LAMP-based COVID-19 testing system called SMART-LAMP (Scalable Molecular Automation for Rapid Testing using LAMP) that can process up to 40,000 samples per day using existing laboratory equipment infrastructure with sensitivity comparable to RT-qPCR. This system provides a rapid and scalable diagnostic solution for future pandemics, capable of processing over 40,000 samples per day. In addition, the system is designed to minimize consumable costs and reduces the overall use of plastics to align with increasingly strict sustainability goals that will be imposed over the coming years. Importantly, this system and public-private partnerships in the TOMi corona initiative has the potential to serve as a baseline to enhance pandemic preparedness and response capabilities., (© The Author(s) 2024. Published by Oxford University Press.)
- Published
- 2024
- Full Text
- View/download PDF
29. Discovery of RNA Biomarkers for Prostate Cancer Using Cross-Platform Transcriptomics.
- Author
-
Visser WCH, de Jong H, Smit FP, Shrivastava J, Poole JC, Leenders WPJ, Melchers WJG, Mulders PFA, and Schalken JA
- Subjects
- Male, Humans, Transcriptome, Oligonucleotide Array Sequence Analysis methods, Gene Expression Regulation, Neoplastic, High-Throughput Nucleotide Sequencing methods, Sequence Analysis, RNA methods, Prostatic Hyperplasia genetics, Prostatic Hyperplasia metabolism, RNA genetics, Prostatic Neoplasms genetics, Prostatic Neoplasms metabolism, Biomarkers, Tumor genetics, Gene Expression Profiling methods
- Abstract
Microarray and Single-Molecule Molecular Inversion Probe (smMIP)-based targeted RNA sequencing are two RNA profiling platforms for identifying disease-associated biomarkers. The microarray uses a GeneChip array with oligonucleotide probes to measure expression levels across thousands of genes, while smMIPs capture and quantify RNA transcripts and transcript variants via next-generation sequencing. To evaluate the strengths and weaknesses of both platforms, a comparative gene expression profiling study was conducted using RNA samples from 52 prostate tissues (normal, benign prostatic hyperplasia (BPH) and various prostate cancer (PCa) grades). Of all genes covered by both platforms, only 35% of the expression levels aligned, with 45% showing discrepancies. Both platforms identified the same 17 genes as potential PCa biomarkers. Microarray analysis identified an additional 253 genes that were not covered or not identified by smMIP technology, while smMIP technology identified eight markers not covered or not identified in the microarray core gene analysis, including fusion genes and splice variants. For high-grade prostate cancer (HG-PCa), the smMIP-method identified 8 markers, and the microarray identified 17 markers, with FOLH1, FAP and CLDN3 being common across both platforms. The choice of RNA expression analysis technology depends on research objectives; microarray technology is useful for the evaluation of a wide range of genes but has low throughput. In contrast, smMIP-based RNA sequencing enables sensitive analysis with minimal RNA in a medium- to high-throughput setting.
- Published
- 2024
- Full Text
- View/download PDF
30. Wild-type MIC distributions and epidemiological cutoff values for 5-flucytosine and Candida species as determined by EUCAST broth microdilution.
- Author
-
Delma FZ, Melchers WJG, Verweij PE, and Buil JB
- Abstract
Objectives: EUCAST has established clinical breakpoints and epidemiological cutoff values (ECOFFs) for Candida spp. However, limited data are available for 5-flucytosine (5-FC). We assessed the in vitro susceptibility of 5-FC against a large collection of clinical Candida species using EUCAST methodology and determined the associated ECOFFs., Methods: A total of 5622 Candida isolates were collected from patients across the Netherlands between 2008 and 2024. 5-FC MICs were determined using the EUCAST microbroth dilution reference method. Furthermore, MICs were extracted from the EUCAST website. The MICs from this study and those extracted were used to determine ECOFFs and local ECOFFs (L-ECOFFs)., Results: 5-FC exhibited potent in vitro activity against C. albicans , N. glabratus and C. parapsilosis, while decreased susceptibility was observed for C. tropicalis, Pichia species, K. marxianus, Y. lipolytica, and C. auris. The ECOFFs (mg/L) and the percentages of WT isolates for 5-FC were: C. albicans : 0.5 (97.2%), N. glabratus : 0.5 (96.6%), C. parapsilosis : 0.5 (99.5%) and P. kudriavzevii : 8 (99.4%). The L-ECOFF (mg/L) and the percentages of WT isolates for 5-FC were: C. dubliniensis : 0.25 (96.8%), C. tropicalis : 0.25 (67.2%), K. marxianus : 0.25 (48.0%), C. lusitaniae : 0.25 (86.5%), M. guillermondii : 0.125 (95.9%) and P. norvegiensis : 8 (94.2%)., Conclusions: 5-FC remains a valuable drug to manage difficult-to-treat invasive Candida infections. In vitro susceptibility cannot be predicted based on species identification for most Candida species, but requires MIC-testing. ECOFFs will help to interpret the MICs to support treatment decisions., (© The Author(s) 2024. Published by Oxford University Press on behalf of British Society for Antimicrobial Chemotherapy.)
- Published
- 2024
- Full Text
- View/download PDF
31. Genetic mutations in Cryptococcus neoformans pyrimidine salvage pathway enzymes contribute to reduced susceptibility against 5-fluorocytosine.
- Author
-
Delma FZ, Yang DH, Cabrera-Orefice A, Coolen J, Al-Hatmi AMS, Ahmed SA, Melchers WJG, Chang YC, Kwon-Chung KJ, de Hoog S, Verweij PE, and Buil JB
- Abstract
Cryptococcal meningitis is a high-mortality infection. Adding 5-fluorocytosine (5-FC) to its treatment improves outcomes, but resistance to 5-FC presents a significant challenge. We conducted whole-genome sequencing on seven C. neoformans isolates with varying 5-FC susceptibility, along with proteomic and in silico analyses. Our findings indicate that mutations in genes of the pyrimidine salvage pathway are responsible for 5-FC resistance. Specifically, we identified an E64G missense mutation in the FUR1 gene, a large deletion in the FCY1 gene, and a point mutation in FCY1 leading to a truncated protein. The proteomic data indicated that these mutations resulted in the absence or reduction of crucial enzymes in resistant isolates. Genetic transformations confirmed the association between these mutations and 5-FC resistance. Resistance to 5-FC can develop during treatment and is closely tied to mutations in key metabolic enzymes. Understanding in vivo resistance development is crucial for combating resistance and enhancing patient outcomes., Competing Interests: Competing interests: P.E.V. reports grants from Gilead Sciences, Mundipharma, Pfizer and F2G, honoraria for lectures for Gilead Sciences and Pfizer and participation in advisory board for F2G, outside the submitted work. All payments were invoiced by the institution. J.B.B. reports grant from Gilead Sciences and F2G, lectures for Gilead Sciences and Pfizer and advisory board for Gilead Sciences outside the submitted work. All payments were invoiced by the institution. All other authors declare no conflict of interest., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
32. HPV integration and cervical cancer: a failed evolutionary viral trait.
- Author
-
Molina MA, Steenbergen RDM, Pumpe A, Kenyon AN, and Melchers WJG
- Subjects
- Humans, Female, Papillomaviridae genetics, Papillomaviridae physiology, Uterine Cervical Neoplasms virology, Uterine Cervical Neoplasms etiology, Virus Integration, Papillomavirus Infections virology, Papillomavirus Infections complications
- Abstract
Countless efforts have been made to eradicate cervical cancer worldwide, including improving disease screening and human papillomavirus (HPV) vaccination programs. Nevertheless, cervical cancer still claims the lives of more than 300 000 women every year. Persistent infections with high-risk HPV genotypes 16 and 18 are the main cause of cancer and may result in HPV integration into the host genome. The central dogma is that HPV integration is an important step in oncogenesis, but in fact, it impedes the virus from replicating and spreading. HPV causing cervical cancer can therefore be perceived as a failed evolutionary viral trait. Here we outline the occurrence and mechanisms of HPV integration and how this process results in oncogenic transformation., Competing Interests: Declaration of interests The authors declare that they have no competing interests., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. [Persistent dermatomycosis due toTrichophyton indotineae].
- Author
-
Buil JB, Meijer EFJ, den Reijer M, Zeeuwen-Franssen MEJ, Melchers WJG, and Verweij PE
- Subjects
- Humans, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Tinea diagnosis, Tinea drug therapy, Tinea microbiology, Trichophyton isolation & purification, Trichophyton drug effects
- Abstract
Trichophyton indotineae is a recently identified dermatophyte that frequently causes extensive and persistent dermatomycosis, particularly tinea corporis, tinea cruris, and tinea faciei. The infection is frequently encountered in countries of the Indian subcontinent and surrounding areas. In Europe, T. indotineae has mainly been detected in patients with an epidemiological link to the aforementioned regions. Unlike dermatomycoses caused by other dermatophyte species, infections caused by T. indotineae often exhibit treatment failure with commonly prescribed antifungal drugs. Reduced susceptibility to terbinafine is often observed in T. indotineae . In addition, reduced susceptibility to itraconazole has also been reported. Due to the extensive and persistent nature of the infection, as well as the reduced susceptibility to antifungal drugs, international experts recommend aggressive treatment of T. indotineae using a combination of oral and topical antifungals. Susceptibility testing may be warranted to guide treatment decisions. Early recognition of T. indotineae infections is crucial to prevent prolonged recurrences.
- Published
- 2024
34. Temporal composition of the cervicovaginal microbiome associates with hrHPV infection outcomes in a longitudinal study.
- Author
-
Molina MA, Leenders WPJ, Huynen MA, Melchers WJG, and Andralojc KM
- Subjects
- Humans, Female, Longitudinal Studies, Adult, Middle Aged, Papillomaviridae genetics, Papillomaviridae isolation & purification, Papillomaviridae classification, Young Adult, Uterine Cervical Neoplasms virology, Uterine Cervical Neoplasms microbiology, Vaginal Smears, Vagina microbiology, Vagina virology, Microbiota, Papillomavirus Infections virology, Papillomavirus Infections microbiology, Cervix Uteri microbiology, Cervix Uteri virology
- Abstract
Background: Persistent infections with high-risk human papillomavirus (hrHPV) can cause cervical squamous intraepithelial lesions (SIL) that may progress to cancer. The cervicovaginal microbiome (CVM) correlates with SIL, but the temporal composition of the CVM after hrHPV infections has not been fully clarified., Methods: To determine the association between the CVM composition and infection outcome, we applied high-resolution microbiome profiling using the circular probe-based RNA sequencing technology on a longitudinal cohort of cervical smears obtained from 141 hrHPV DNA-positive women with normal cytology at first visit, of whom 51 were diagnosed by cytology with SIL six months later., Results: Here we show that women with a microbial community characterized by low diversity and high Lactobacillus crispatus abundance at both visits exhibit low risk to SIL development, while women with a microbial community characterized by high diversity and Lactobacillus depletion at first visit have a higher risk of developing SIL. At the level of individual species, we observed that a high abundance for Gardnerella vaginalis and Atopobium vaginae at both visits associate with SIL outcomes. These species together with Dialister micraerophilus showed a moderate discriminatory power for hrHPV infection progression., Conclusions: Our results suggest that the CVM can potentially be used as a biomarker for cervical disease and SIL development after hrHPV infection diagnosis with implications on cervical cancer prevention strategies and treatment of SIL., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. Prognostic value of HPV-PCR, p16 and p53 immunohistochemical status on local recurrence rate and survival in patients with vulvar squamous cell carcinoma.
- Author
-
Pouwer AW, Te Grootenhuis NC, Hinten F, de Bock GH, van der Zee AGJ, Melchers WJG, Oonk MHM, de Hullu JA, Hollema H, and Bulten J
- Subjects
- Humans, Female, Middle Aged, Aged, Prognosis, Adult, Aged, 80 and over, Papillomaviridae isolation & purification, Papillomaviridae genetics, Polymerase Chain Reaction, Vulvar Neoplasms virology, Vulvar Neoplasms pathology, Vulvar Neoplasms mortality, Carcinoma, Squamous Cell virology, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell metabolism, Tumor Suppressor Protein p53 analysis, Tumor Suppressor Protein p53 metabolism, Cyclin-Dependent Kinase Inhibitor p16 analysis, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Neoplasm Recurrence, Local virology, Neoplasm Recurrence, Local pathology, Immunohistochemistry, Papillomavirus Infections complications, Papillomavirus Infections virology, Papillomavirus Infections diagnosis, Papillomavirus Infections pathology, Biomarkers, Tumor analysis
- Abstract
The primary aim of this study was to assess the association between human papilloma virus (HPV) and p53 expression and local recurrence (LR), disease specific survival (DSS), and overall survival (OS) in patients with vulvar squamous cell carcinoma (VSCC). Secondary, the accuracy of p16 immunohistochemistry for HPV status was assessed. The tumor tissue of 255 patients, surgically treated for primary unifocal VSCC between 2000 and 2010, was analyzed. HPV-PCR and P16 and p53 immunohistochemical stainings were performed. All histologic slides were independently reviewed by two expert gyneco-pathologists. Time to first LR, DSS, and OS for the variables p16, p53, and HPV-PCR were compared using univariable and multivariable Cox-regression analyses. In 211/255 (83.5%) patients, HPV-PCR was negative. The local recurrence rate was significantly lower in patients positive with HPV-PCR (10-year LR rate 24.6%) versus negative tumors (47.5%), p = 0.004. After multivariable analyses, this difference remained significant (HR 0.23 (95% CI 0.08-0.62) p = 0.004). There was no difference in LR rate correlated to the p53 expression. DSS and OS did not significantly differ after multivariable analyses for all different subgroups. Sensitivity and specificity of p16 staining for presence of HPV detected by HPV-PCR were 86.4% and 93.8%, respectively. In conclusion, patients with HPV-negative VSCCs have significantly more LR compared to patients with HPV-positive VSCCs, and p16 immunohistochemistry is a reliable surrogate marker for HPV status. No relevant subgroup for LR or survival based on HPV/p53 status could be identified. We advise to perform an HPV-PCR or p16 IHC staining in all patients with VSCC., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
36. Antifungal Resistance in Pulmonary Aspergillosis.
- Author
-
Verweij PE, Song Y, Buil JB, Zhang J, and Melchers WJG
- Subjects
- Humans, Antifungal Agents pharmacology, Antifungal Agents therapeutic use, Aspergillus fumigatus genetics, Aspergillus, Chronic Disease, Persistent Infection, Pulmonary Aspergillosis drug therapy, Pulmonary Aspergillosis diagnosis, Pulmonary Aspergillosis microbiology, Aspergillosis, Allergic Bronchopulmonary drug therapy, Cystic Fibrosis drug therapy
- Abstract
Aspergilli may cause various pulmonary diseases in humans, including allergic bronchopulmonary aspergillosis (ABPA), chronic pulmonary aspergillosis (CPA), and acute invasive pulmonary aspergillosis (IPA). In addition, chronic colonization may occur in cystic fibrosis (CF). Aspergillus fumigatus represents the main pathogen, which may employ different morphotypes, for example, conidia, hyphal growth, and asexual sporulation, in the various Aspergillus diseases. These morphotypes determine the ease by which A. fumigatus can adapt to stress by antifungal drug exposure, usually resulting in one or more resistance mutations. Key factors that enable the emergence of resistance include genetic variation and selection. The ability to create genetic variation depends on the reproduction mode, including, sexual, parasexual, and asexual, and the population size. These reproduction cycles may take place in the host and/or in the environment, usually when specific conditions are present. Environmental resistance is commonly characterized by tandem repeat (TR)-mediated mutations, while in-host resistance selection results in single-resistance mutations. Reported cases from the literature indicate that environmental resistance mutations are almost exclusively present in patients with IA indicating that the risk for in-host resistance selection is very low. In aspergilloma, single-point mutations are the dominant resistance genotype, while in other chronic Aspergillus diseases, for example, ABPA, CPA, and CF, both TR-mediated and single-resistance mutations are reported. Insights into the pathogenesis of resistance selection in various Aspergillus diseases may help to improve diagnostic and therapeutic strategies., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
37. Early detection of active Human CytomegaloVirus (hCMV) infection in pregnant women using data generated for noninvasive fetal aneuploidy testing.
- Author
-
Faas BHW, Astuti G, Melchers WJG, Reuss A, Gilissen C, Macville MVE, Ghesquiere SAI, Houben LMH, Srebniak MI, Geeven G, Rahamat-Langendoen JC, Sistermans EA, and Linthorst J
- Subjects
- Infant, Newborn, Humans, Female, Pregnancy, Pregnant People, Aneuploidy, Prenatal Diagnosis methods, Cytomegalovirus genetics, Cell-Free Nucleic Acids
- Abstract
Background: Prenatal hCMV infections can lead to severe embryopathy and neurological sequelae in neonates. Screening during pregnancy is not recommended by global societies, as there is no effective therapy. Recently, several groups showed that maternal-fetal hCMV transmission can be strongly reduced by administering anti-viral agents early in pregnancy. This calls for a screening method to identify at risk pregnancies at an appropriate gestational age, with the possibility for large-scale enrolment. Non-Invasive Prenatal Testing (NIPT) for fetal aneuploidy screening early in pregnancy is already implemented in many countries and performed on a large-scale basis. We investigated the use of whole genome cell-free DNA (cfDNA) sequencing data, generated for the purpose of NIPT, as (pre-)screening tool to identify women with active hCMV-infections, eligible for therapy., Methods: Coded raw sequencing NIPT data from 204,818 pregnant women from three testing laboratories were analyzed for the presence of hCMV-cfDNA. Samples were stratified by cfDNA-hCMV load. For validation and interpretation, diagnostic hCMV-qPCR and serology testing were performed on a subset of cfDNA-hCMV-positive (n = 112) and -negative (n = 127) samples., Findings: In 1930 samples (0.94%) hCMV fragments were detected. Validation by hCMV-qPCR showed that samples with high cfDNA-hCMV load tested positive and cfDNA-hCMV-negative samples tested negative. In 32/112 cfDNA-hCMV-positive samples (28.6%) the serological profile suggested a recent primary infection: this was more likely in samples with high cfDNA-hCMV load (78.6%) than in samples with low cfDNA-hCMV load (11.0%). In none of the cfDNA-hCMV-negative samples serology was indicative of a recent primary infection., Interpretation: Our study shows that large-scale (pre-)screening for both genetic fetal aberrations and active maternal hCMV infections during pregnancy can be combined in one cfDNA sequencing test, performed on a single blood sample, drawn in the first trimester of pregnancy., Funding: This work was partly funded by the Prenatal Screening Foundation Nijmegen, the Netherlands., Competing Interests: Declaration of interests EAS declares to have received a grant for research with focus on the heel prick. He is a board member of the Dutch Society for Laboratory specialists clinical genetics and of the Genomics Quality Assessment consortium (GenQA), and received support for attending conferences from the latter. The other authors declare no conflicts of interest., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
38. Aspergillus Outbreak in an Intensive Care Unit: Source Analysis with Whole Genome Sequencing and Short Tandem Repeats.
- Author
-
Hiel SJP, Hendriks ACA, Eijkenboom JJA, Bosch T, Coolen JPM, Melchers WJG, Anröchte P, Camps SMT, Verweij PE, Zhang J, and Dommelen LV
- Abstract
Whole genome sequencing (WGS) is widely used for outbreak analysis of bacteriology and virology but is scarcely used in mycology. Here, we used WGS for genotyping Aspergillus fumigatus isolates from a potential Aspergillus outbreak in an intensive care unit (ICU) during construction work. After detecting the outbreak, fungal cultures were performed on all surveillance and/or patient respiratory samples. Environmental samples were obtained throughout the ICU. WGS was performed on 30 isolates, of which six patient samples and four environmental samples were related to the outbreak, and twenty samples were unrelated, using the Illumina NextSeq 550. A SNP-based phylogenetic tree was created from outbreak samples and unrelated samples. Comparative analysis (WGS and short tandem repeats (STRs), microsatellite loci analysis) showed that none of the strains were related to each other. The lack of genetic similarity suggests the accumulation of Aspergillus spores in the hospital environment, rather than a single source that supported growth and reproduction of Aspergillus fumigatus . This supports the hypothesis that the Aspergillus outbreak was likely caused by release of Aspergillus fumigatus spores during construction work. Indeed, no new Aspergillus cases were observed in the ICU after cessation of construction. This study demonstrates that WGS is a suitable technique for examining inter-strain relatedness of Aspergillus fumigatus in the setting of an outbreak investigation., Competing Interests: The authors declare no conflict of interest.
- Published
- 2024
- Full Text
- View/download PDF
39. The emerging role of Lactobacillus acidophilus in the cervicovaginal microenvironment.
- Author
-
Molina MA, Melchers WJG, Núñez-Samudio V, and Landires I
- Subjects
- Lactobacillus, Lactobacillus acidophilus, Probiotics pharmacology, Probiotics therapeutic use
- Abstract
Competing Interests: We declare no competing interests.
- Published
- 2024
- Full Text
- View/download PDF
40. The diagnostic accuracy of the GeneXpert ESBL- ampC prototype assay for rapid PCR-based detection of extended-spectrum beta-lactamase genes directly from urine.
- Author
-
Tops SCM, Schapendonk CEP, Coolen JPM, Tenover FC, Tickler IA, Melchers WJG, and Wertheim HFL
- Subjects
- Humans, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents therapeutic use, Carbapenems, Polymerase Chain Reaction, Microbial Sensitivity Tests, beta-Lactamases genetics, Urinary Tract Infections diagnosis, Urinary Tract Infections drug therapy
- Abstract
Importance: Early identification of complicated urinary tract infections caused by ESBL-producing Enterobacterales has the potential to limit the use of carbapenems to those patients without alternative antibiotic options and avoid the empirical use of carbapenems in patients without ESBL-producing bacteria. The purpose for such a test will differ by setting and ESBL prevalence rates. Countries with low ESBL rates and cephalosporins as empiric treatment (e.g., The Netherlands) will need a rule-in test to decide to use carbapenems, while countries with high ESBL rates and empiric carbapenem treatment will need a rule-out test for ESBLs to de-escalate therapy early. Anyway, such as a test would-at least theoretically-improve patient care and reduce selective pressure for the emergence of carbapenem resistance., Competing Interests: This Radboudumc researcher-initiated study was supported in kind with free testing cartridges by Cepheid. I.A.T. is an employee of Cepheid, and F.C.T. is a former Cepheid employee.
- Published
- 2023
- Full Text
- View/download PDF
41. Methodological and analytical challenges in microbiome-HPV association studies.
- Author
-
Molina MA and Melchers WJG
- Subjects
- Humans, Female, Papillomavirus Infections, Microbiota, Uterine Cervical Neoplasms
- Published
- 2023
- Full Text
- View/download PDF
42. Longitudinal analysis on the ecological dynamics of the cervicovaginal microbiome in hrHPV infection.
- Author
-
Molina MA, Melchers WJG, Andralojc KM, Leenders WPJ, and Huynen MA
- Abstract
The cervicovaginal microbiome (CVM) is a dynamic continuous microenvironment that can be clustered in microbial community state types (CSTs) and is associated with women's cervical health. Lactobacillus -depleted communities particularly associate with an increased susceptibility for persistence of high-risk human papillomavirus (hrHPV) infections and progression of disease, but the long-term ecological dynamics of CSTs after hrHPV infection diagnosis remain poorly understood. To determine such dynamics, we examined the CVM of our longitudinal cohort of 141 women diagnosed with hrHPV infection at baseline with collected cervical smears at two timepoints six-months apart. Here we describe that the long-term microbiome dissimilarity has a positive correlation with microbial diversity at both visits and that women with high abundance and dominance for Lactobacillus iners at baseline exhibit more similar microbiome composition at second visit than women with Lactobacillus -depleted communities at baseline. We further show that the species Lactobacillus acidophilus and Megasphaera genomosp type 1 associate with CST changes between both visits. Lastly, we also observe that Gardnerella vaginalis is associated with the stability of Lactobacillus -depleted communities while L. iners is associated with the instability of Megasphaera genomosp type 1 -dominated communities. Our data suggest dynamic patterns of cervicovaginal CSTs during hrHPV infection, which could be potentially used to develop microbiome-based therapies against infection progression towards disease., Competing Interests: The authors declare no competing non-financial interests but the following competing financial interests: William P. J. Leenders is CSO and shareholder of Predica Diagnostics., (© 2023 The Authors.)
- Published
- 2023
- Full Text
- View/download PDF
43. The C 2 H 2 transcription factor SltA is required for germination and hyphal development in Aspergillus fumigatus .
- Author
-
Baltussen TJH, van Rhijn N, Coolen JPM, Dijksterhuis J, Verweij PE, Bromley MJ, and Melchers WJG
- Subjects
- Humans, Transcription Factors genetics, Hyphae, Aspergillus, Aspergillus fumigatus, Aspergillosis microbiology
- Abstract
Germination of inhaled Aspergillus fumigatus conidia is a necessary sequitur for infection. Germination of conidia starts with the breaking of dormancy, which is initiated by an increase of the cellular perimeter in a process termed isotropic growth. This swelling phase is followed by polarized growth, resulting in the formation of a germ tube. The multinucleate tubular cells exhibit tip growth from the hyphae, after which lateral branches emerge to form the mycelial network. The regulatory mechanisms governing conidial germination are not well defined. In this study, we identified a novel role for the transcription factor SltA in the orchestration of germination and hyphal development. Conidia lacking sltA fail to appropriately regulate isotropic growth and begin to swell earlier and subsequently switch to polarized growth faster. Additionally, hyphal development is distorted in a ∆ sltA isolate as hyphae are hyper-branching and wider, and show branching at the apical tip. ∆ sltA conidia are more tolerant to cell wall stressors on minimal medium compared to the wild-type (WT) strain. A transcriptome analysis of different stages of early growth was carried out to assess the regulatory role of SltA. Null mutants generated for three of the most dysregulated genes showed rapid germ tube emergence. Distinct from the phenotype observed for ∆ sltA , conidia from these strains lacked defects in isotropic growth, but switched to polarized growth faster. Here, we characterize and describe several genes in the regulon of SltA, highlighting the complex nature of germination.IMPORTANCE Aspergillus fumigatus is the main human fungal pathogen causing aspergillosis. For this fungus, azoles are the most commonly used antifungal drugs for treatment of aspergillosis. However, the prevalence of azole resistance is alarmingly increasing and linked with elevated mortality. Germination of conidia is crucial within its asexual life cycle and plays a critical role during the infection in the human host. Precluding germination could be a promising strategy considering the role of germination in Aspergillus spp. pathogenicity. Here, we identify a novel role for SltA in appropriate maintenance of dormancy, germination, and hyphal development. Three genes in the regulon of SltA were also essential for appropriate germination of conidia. With an expanding knowledge of germination and its different morphotypes, more advances can be made toward potential anti-germination targets for therapy., Competing Interests: P.E.V received research grants from Gilead Sciences, Pfizer, MSD, F2G, and Mundipharma outside of the submitted work, is a speaker for Gilead Sciences and MSD, and is on the advisory boards for Pfizer, MSD, and F2G. M.J.B. is a consultant to Synlab GmbH, is the director and shareholder of Syngenics Limited, and is a substantive shareholder in PiQ Laboratories Ltd. The remaining authors declare no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
44. Acceptability of risk-based triage in cervical cancer screening: A focus group study.
- Author
-
Bas S, Sijben J, Bischoff EWMA, Bekkers RLM, de Kok IMCM, Melchers WJG, Siebers AG, van der Waal D, and Broeders MJM
- Subjects
- Female, Humans, Middle Aged, Pregnancy, Early Detection of Cancer, Triage, Focus Groups, Cytodiagnosis, Papillomaviridae, Mass Screening, Colposcopy, Uterine Cervical Neoplasms, Papillomavirus Infections, Uterine Cervical Dysplasia diagnosis
- Abstract
Background: Compared to the previous cytology-based program, the introduction of primary high-risk human papillomavirus (hrHPV) based screening in 2017 has led to an increased number of referrals. To counter this, triage of hrHPV-positive women in cervical cancer screening can potentially be optimized by taking sociodemographic and lifestyle risk factors for cervical abnormalities into account. Therefore, it is essential to gain knowledge of the views of women (30-60 years) eligible for cervical cancer screening., Objective: The main goal of this qualitative study was to gain insight in the aspects that influence acceptability of risk-based triage in cervical cancer screening., Design: A focus group study in which participants were recruited via four general medical practices, and purposive sampling was used to maximize heterogeneity with regards to age, education level, and cervical cancer screening experiences., Approach: The focus group discussions were transcribed verbatim and analyzed using reflexive thematic analysis., Participants: A total of 28 women (average age: 45.2 years) eligible for cervical cancer screening in The Netherlands participated in seven online focus group discussions. Half of the participants was higher educated, and the participants differed in previous cervical cancer screening participation and screening result., Key Results: In total, 5 main themes and 17 subthemes were identified that determine the acceptability of risk-stratified triage. The main themes are: 1) adequacy of the screening program: an evidence-based program that is able to minimize cancer incidence and reduce unnecessary referrals; 2) personal information (e.g., sensitive topics and stigma); 3) emotional impact: fear and reassurance; 4) communication (e.g., transparency); and 5) autonomy (e.g., prevention)., Conclusion: The current study highlights several challenges regarding the development and implementation of risk-based triage that need attention in order to be accepted by the target group. These challenges include dealing with sensitive topics and a transparent communication strategy., Competing Interests: The authors have declared that no competing interests exist., (Copyright: © 2023 Bas et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.)
- Published
- 2023
- Full Text
- View/download PDF
45. The Transcriptome Response to Azole Compounds in Aspergillus fumigatus Shows Differential Gene Expression across Pathways Essential for Azole Resistance and Cell Survival.
- Author
-
Hokken MWJ, Coolen JPM, Steenbreker H, Zoll J, Baltussen TJH, Verweij PE, and Melchers WJG
- Abstract
The opportunistic pathogen Aspergillus fumigatus is found on all continents and thrives in soil and agricultural environments. Its ability to readily adapt to novel environments and to produce billions of spores led to the spread of azole-resistant A. fumigatus across the globe, posing a threat to many immunocompromised patients, including critically ill patients with severe influenza or COVID-19. In our study, we sought to compare the adaptational response to azoles from A. fumigatus isolates that differ in azole susceptibility and genetic background. To gain more insight into how short-term adaptation to stressful azole compounds is managed through gene expression, we conducted an RNA-sequencing study on the response of A. fumigatus to itraconazole and the newest clinically approved azole, isavuconazole. We observed many similarities in ergosterol biosynthesis up-regulation across isolates, with the exception of the pan-azole-resistant isolate, which showed very little differential regulation in comparison to other isolates. Additionally, we found differential regulation of membrane efflux transporters, secondary metabolites, iron metabolism, and various stress response and cell signaling mechanisms., Competing Interests: The authors declare that they have no competing interests.
- Published
- 2023
- Full Text
- View/download PDF
46. Evaluation of DNA methylation biomarkers ASCL1 and LHX8 on HPV-positive self-collected samples from primary HPV-based screening.
- Author
-
Verhoef L, Bleeker MCG, Polman N, Steenbergen RDM, Ebisch RMF, Melchers WJG, Bekkers RLM, Molijn AC, Quint WG, van Kemenade F, Meijer CJLM, Berkhof J, and Heideman DAM
- Subjects
- Humans, Female, DNA Methylation, Early Detection of Cancer methods, Biomarkers, Basic Helix-Loop-Helix Transcription Factors genetics, Uterine Cervical Neoplasms diagnosis, Uterine Cervical Neoplasms genetics, Uterine Cervical Dysplasia, Papillomavirus Infections
- Abstract
Background: Host-cell DNA methylation analysis can be used to triage women with high-risk human papillomavirus (HPV)-positive self-collected cervicovaginal samples, but current data are restricted to under-/never-screened women and referral populations. This study evaluated triage performance in women who were offered primary HPV self-sampling for cervical cancer screening., Methods: Self-collected samples from 593 HPV-positive women who participated in a primary HPV self-sampling trial (IMPROVE study; NTR5078), were tested for the DNA methylation markers ASCL1 and LHX8 using quantitative multiplex methylation-specific PCR (qMSP). The diagnostic performance for CIN3 and cervical cancer (CIN3 + ) was evaluated and compared with that of paired HPV-positive clinician-collected cervical samples., Results: Significantly higher methylation levels were found in HPV-positive self-collected samples of women with CIN3 + than control women with no evidence of disease (P values <0.0001). The marker panel ASCL1/LHX8 yielded a sensitivity for CIN3 + detection of 73.3% (63/86; 95% CI 63.9-82.6%), with a corresponding specificity of 61.1% (310/507; 95% CI 56.9-65.4%). The relative sensitivity for detecting CIN3+ was 0.95 (95% CI 0.82-1.10) for self-collection versus clinician-collection, and the relative specificity was 0.82 (95% CI 0.75-0.90)., Conclusions: The ASCL1/LHX8 methylation marker panel constitutes a feasible direct triage method for the detection of CIN3 + in HPV-positive women participating in routine screening by self-sampling., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
47. Targeting the 16S rRNA Gene by Reverse Complement PCR Next-Generation Sequencing: Specific and Sensitive Detection and Identification of Microbes Directly in Clinical Samples.
- Author
-
Moorlag SJCFM, Coolen JPM, van den Bosch B, Jin EH, Buil JB, Wertheim HFL, and Melchers WJG
- Subjects
- Humans, RNA, Ribosomal, 16S genetics, Genes, rRNA, Sequence Analysis, DNA methods, Polymerase Chain Reaction methods, High-Throughput Nucleotide Sequencing methods, DNA, Bacterial genetics, Bacteria, Bacterial Infections microbiology
- Abstract
The detection and accurate identification of bacterial species in clinical samples are crucial for diagnosis and appropriate antibiotic treatment. To date, sequencing of the 16S rRNA gene has been widely used as a complementary molecular approach when identification by culture fails. The accuracy and sensitivity of this method are highly affected by the selection of the 16S rRNA gene region targeted. In this study, we assessed the clinical utility of 16S rRNA reverse complement PCR (16S RC-PCR), a novel method based on next-generation sequencing (NGS), for the identification of bacterial species. We investigated the performance of 16S RC-PCR on 11 bacterial isolates, 2 polymicrobial community samples, and 59 clinical samples from patients suspected of having a bacterial infection. The results were compared to culture results, if available, and to the results of Sanger sequencing of the 16S rRNA gene (16S Sanger sequencing). By 16S RC-PCR, all bacterial isolates were accurately identified to the species level. Furthermore, in culture-negative clinical samples, the rate of identification increased from 17.1% (7/41) to 46.3% (19/41) when comparing 16S Sanger sequencing to 16S RC-PCR. We conclude that the use of 16S RC-PCR in the clinical setting leads to an increased sensitivity of detection of bacterial pathogens, resulting in a higher number of diagnosed bacterial infections, and thereby can improve patient care. IMPORTANCE The identification of the causative infectious pathogen in patients suspected of having a bacterial infection is essential for diagnosis and the start of appropriate treatment. Over the past 2 decades, molecular diagnostics have improved the ability to detect and identify bacteria. However, novel techniques that can accurately detect and identify bacteria in clinical samples and that can be implemented in clinical diagnostics are needed. Here, we demonstrate the clinical utility of bacterial identification in clinical samples by a novel method called 16S RC-PCR. Using 16S RC-PCR, we reveal a significant increase in the number of clinical samples in which a potentially clinically relevant pathogen is identified compared to the commonly used 16S Sanger method. Moreover, RC-PCR allows automation and is well suited for implementation in a diagnostic laboratory. In conclusion, the implementation of this method as a diagnostic tool is expected to result in an increased number of diagnosed bacterial infections, and in combination with adequate treatment, this could improve clinical outcomes for patients., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
48. The Siderophore Ferricrocin Mediates Iron Acquisition in Aspergillus fumigatus.
- Author
-
Happacher I, Aguiar M, Alilou M, Abt B, Baltussen TJH, Decristoforo C, Melchers WJG, and Haas H
- Subjects
- Humans, Aspergillus fumigatus metabolism, Iron metabolism, Siderophores, Ferrichrome metabolism
- Abstract
The opportunistic fungal pathogen Aspergillus fumigatus utilizes two high-affinity iron uptake mechanisms, termed reductive iron assimilation (RIA) and siderophore-mediated iron acquisition (SIA). The latter has been shown to be crucial for virulence of this fungus and is a target for development of novel strategies for diagnosis and treatment of fungal infections. So far, research on SIA in this mold focused mainly on the hyphal stage, revealing the importance of extracellular fusarinine-type siderophores in iron acquisition as well as of the siderophore ferricrocin in intracellular iron handling. The current study aimed to characterize iron acquisition during germination. High expression of genes involved in biosynthesis and uptake of ferricrocin in conidia and during germination, independent of iron availability, suggested a role of ferricrocin in iron acquisition during germination. In agreement, (i) bioassays indicated secretion of ferricrocin during growth on solid media during both iron sufficiency and limitation, (ii) ferricrocin was identified in the supernatant of conidia germinating in liquid media during both iron sufficiency and limitation, (iii) in contrast to mutants lacking all siderophores, mutants synthesizing ferricrocin but lacking fusarinine-type siderophores were able to grow under iron limitation in the absence of RIA, and (iv) genetic inactivation of the ferricrocin transporter Sit1 decreased germination in the absence of RIA. Taken together, this study revealed that ferricrocin has not only an intracellular role but also functions as an extracellular siderophore to support iron acquisition. The iron availability-independent ferricrocin secretion and uptake during early germination indicate developmental, rather than iron regulation. IMPORTANCE Aspergillus fumigatus is one of the most common airborne fungal pathogens for humans. Low-molecular-mass iron chelators, termed siderophores, have been shown to play a central role in iron homeostasis and, consequently, virulence of this mold. Previous studies demonstrated the crucial role of secreted fusarinine-type siderophores, such as triacetylfusarinine C, in iron acquisition, as well as of the ferrichrome-type siderophore ferricrocin in intracellular iron storage and transport. Here, we demonstrate that ferricrocin is also secreted to mediate iron acquisition during germination together with reductive iron assimilation. During early germination, ferricrocin secretion and uptake were not repressed by iron availability, indicating developmental regulation of this iron acquisition system in this growth phase., Competing Interests: The authors declare no conflict of interest.
- Published
- 2023
- Full Text
- View/download PDF
49. Retrospective Multicenter Evaluation of the VirClia Galactomannan Antigen Assay for the Diagnosis of Pulmonary Aspergillosis with Bronchoalveolar Lavage Fluid Samples from Patients with Hematological Disease.
- Author
-
Buil JB, Huygens S, Dunbar A, Schauwvlieghe A, Reynders M, Langerak D, van Dijk K, Bruns A, Haas PJ, Postma DF, Biemond B, Delma FZ, de Kort E, Melchers WJG, Verweij PE, and Rijnders B
- Subjects
- Humans, Retrospective Studies, Bronchoalveolar Lavage Fluid microbiology, Mannans analysis, Sensitivity and Specificity, Pulmonary Aspergillosis, Invasive Pulmonary Aspergillosis diagnosis, Hematologic Diseases
- Abstract
Galactomannan (GM) testing of bronchoalveolar lavage (BAL) fluid samples has become an essential tool to diagnose invasive pulmonary aspergillosis (IPA) and is part of diagnostic guidelines. Enzyme-linked immunosorbent assays (ELISAs) (enzyme immunoassays [EIAs]) are commonly used, but they have a long turnaround time. In this study, we evaluated the performance of an automated chemiluminescence immunoassay (CLIA) with BAL fluid samples. This was a multicenter retrospective study in the Netherlands and Belgium. BAL fluid samples were collected from patients with underlying hematological diseases with a suspected invasive fungal infection. Diagnosis of IPA was based on the 2020 European Organisation for Research and Treatment of Cancer (EORTC)/Mycoses Study Group Education and Research Consortium (MSGERC) consensus definitions. GM results were reported as optical density index (ODI) values. ODI cutoff values for positive results that were evaluated were 0.5, 0.8, and 1.0 for the EIA and 0.16, 0.18, and 0.20 for the CLIA. Probable IPA cases were compared with two control groups, one with no evidence of IPA and another with no IPA or possible IPA. Qualitative agreement was analyzed using Cohen's κ, and quantitative agreement was analyzed by Spearman's correlation. We analyzed 141 BAL fluid samples from 141 patients; 66 patients (47%) had probable IPA, and 56 cases remained probable IPA when the EIA GM result was excluded as a criterion, because they also had positive culture and/or duplicate positive PCR results. Sixty-three patients (45%) had possible IPA and 12 (8%) had no IPA. The sensitivity and specificity of the two tests were quite comparable, and the overall qualitative agreement between EIA and CLIA results was 81 to 89%. The correlation of the actual CLIA and EIA values was strong at 0.72 (95% confidence interval, 0.63 to 0.80). CLIA has similar performance, compared to the gold-standard EIA, with the benefits of faster turnaround because batching is not required. Therefore, CLIA can be used as an alternative GM assay for BAL fluid samples., Competing Interests: The authors declare a conflict of interest. J.B.B. received research grants from Gilead Sciences and F2G Ltd. E.d.K. received a research grant from Gilead Sciences. B.R. received a research grant from Gilead Sciences. He received consulting fees from F2G Ltd and support for meetings from Pfizer, Gilead Sciences an F2G Ltd. S.H. declares to have received travel support from Gilead Sciences. P.E.V. reports grants received from Gilead Sciences, MSD, Pfizer, Mundipharma and F2G, and non-financial support from OLM and IMMY. B.R. participated in the DSMB by Exevir and received travel support to medical conferences by Gilead Sciences and Pfizer., A.S., P.-J.H., D.L., B.B., N.B. M.R., A.B., D.F.P., A.D., K.v.D., F.Z.D., W.J.G.M. declared to have no conflict of interests.
- Published
- 2023
- Full Text
- View/download PDF
50. MGIT Enriched Shotgun Metagenomics for Routine Identification of Nontuberculous Mycobacteria: a Route to Personalized Health Care.
- Author
-
Schildkraut JA, Coolen JPM, Severin H, Koenraad E, Aalders N, Melchers WJG, Hoefsloot W, Wertheim HFL, and van Ingen J
- Subjects
- Humans, Nontuberculous Mycobacteria, Phylogeny, Mycobacterium Infections, Nontuberculous diagnosis, Mycobacterium Infections, Nontuberculous microbiology, Mycobacterium, Mycobacterium marinum
- Abstract
Currently, nontuberculous mycobacteria (NTM) are identified using small genomic regions, and species-level identification is often not possible. We introduce a next-generation sequencing (NGS) workflow that identifies mycobacteria to (sub)species level on the basis of the whole genome extracted from enriched shotgun metagenomic data. This technique is used to study the association between genotypes and clinical manifestations to pave the way to more personalized health care. Two sets of clinical isolates (explorative set [ n = 212] and validation set [ n = 235]) were included. All data were analyzed using a custom pipeline called MyCodentifier. Sequences were matched against a custom hsp65 database (NGS- hsp65 ) and whole-genome database (NGS-WG) created based on the phylogeny presented by Tortoli et al. (E. Tortoli, T. Fedrizzi, C. J. Meehan, A. Trovato, et al., Infect Genet Evol 56:19-25, 2017, https://doi.org/10.1016/j.meegid.2017.10.013). Lastly, phylogenetic analysis was performed and correlated with clinical manifestation. In the explorative set, we observed 98.6% agreement between the line probe assay and the NGS- hsp65 database. In the validation set, 99.1% agreement between the NGS-WG and NGS- hsp65 databases was seen on the complex level. We identified a cluster of Mycobacterium marinum isolates not represented by the Tortoli et al. phylogeny. Phylogenetic analysis of M. avium complex isolates confirmed misclassification of M. timonense and M. bouchedurhonense and identified subclusters within M. avium although no correlation with clinical manifestation was observed. We performed routine NGS to identify NTM from MGIT enriched shotgun metagenomic data. Phylogenetic analyses identified subtypes of M. avium, but in our set of isolates no correlation with clinical manifestation was found. However, this NGS workflow paves a way for more personalized health care in the future.
- Published
- 2023
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.